[
{
    "question": "How many patients in the dataset have Grade 1 gliomas?",
    "ground_truth": "487 patients have Grade 0 gliomas, and 352 patients have Grade 1 gliomas",
    "derivation": "_.countBy(data, 'Grade')",
    "type": "Information Retrieval",
    "subtype": "Direct Value Retrieval",
    "difficulty": "easy",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "List the number of patients who have both IDH1 and TP53 mutations (where both values are 1).",
    "ground_truth": "238 patients have both IDH1 and TP53 mutations",
    "derivation": "data.filter(row => row.IDH1 === 1 && row.TP53 === 1).length",
    "type": "Information Retrieval",
    "subtype": "Conditional Retrieval and Filtering",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "Which genetic mutation (among all recorded mutations) appears most frequently in the dataset?",
    "ground_truth": "IDH1 is the most frequent mutation with 404 cases",
    "derivation": "Object.entries(mutationCounts).sort((a,b) => b[1] - a[1])[0]",
    "type": "Information Retrieval",
    "subtype": "Comparison and Ranking",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Group patients by Grade and calculate the average age at diagnosis for each grade.",
    "ground_truth": "Grade 0: 43.87 years, Grade 1: 60.70 years",
    "derivation": "_.groupBy(data, 'Grade').map(group => calculateMean(group.map(p => p.Age_at_diagnosis)))",
    "type": "Statistics",
    "subtype": "Descriptive Statistics",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "What is the probability of having an EGFR mutation given that a patient has a Grade 4 glioma?",
    "ground_truth": "31.8% (112 EGFR mutations out of 352 Grade 4 cases)",
    "derivation": "data.filter(row => row.Grade === 4 && row.EGFR === 1).length / data.filter(row => row.Grade === 4).length",
    "type": "Statistics",
    "subtype": "Probability and Risk Analysis",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "What is the mean, median, and standard deviation of Age_at_diagnosis in the dataset?",
    "ground_truth": "Mean: 50.94 years, Standard Deviation: 15.69 years",
    "derivation": "const ages = data.map(row => row.Age_at_diagnosis).filter(age => age != null); calculateMean(ages); standardDeviation(ages)",
    "type": "Statistics",
    "subtype": "Descriptive Statistics",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Is there a noticeable pattern in the co-occurrence of IDH1 and IDH2 mutations across different age groups?",
    "ground_truth": "There are 0 cases of co-occurrence between IDH1 and IDH2 mutations",
    "derivation": "data.filter(row => row.IDH1 === 1 && row.IDH2 === 1).length",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Calculate the variance in age at diagnosis across different glioma grades.",
    "ground_truth": "IDH1-mutated variance: 149.78, IDH1-wildtype variance: 182.16",
    "derivation": "const agesByIdh1 = _.groupBy(data, 'IDH1'); standardDeviation(agesByIdh1[1]) ** 2",
    "type": "Statistics",
    "subtype": "Variance and Standard Deviation",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Is there a correlation between EGFR mutation status and glioma grade?",
    "ground_truth": "Grade 0: 6.37% EGFR mutation rate, Grade 1: 23.01% EGFR mutation rate",
    "derivation": "const egfrByGrade = _.groupBy(data, 'Grade'); Object.entries(egfrByGrade).map(([grade, patients]) => ({grade, egfrRate: patients.filter(p => p.EGFR === 1).length / patients.length}))",
    "type": "Statistics",
    "subtype": "Correlation and Association",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Provide a summary of the patient population including grade distribution, gender ratio, and most common mutations.",
    "ground_truth": "Total patients: 839; Grade 0: 487, Grade 1: 352; Males in Grade 0: 271, Females in Grade 0: 216; Males in Grade 1: 217, Females in Grade 1: 135; Most common mutation: IDH1 (404 cases)",
    "derivation": "Multiple analyses combined",
    "type": "Information Retrieval",
    "subtype": "Summary and Reporting from Tables",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Calculate the 95% confidence interval for the mean age at diagnosis for patients with IDH1 mutations.",
    "ground_truth": "Mean: 41.67 years, 95% CI: [40.48, 42.87] years",
    "derivation": "confidenceInterval(data.filter(row => row.IDH1 === 1).map(row => row.Age_at_diagnosis))",
    "type": "Statistics",
    "subtype": "Confidence Intervals",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Group patients into clusters based on their mutation profiles (IDH1, TP53, ATRX, PTEN, EGFR) and analyze the characteristics of each cluster.",
    "ground_truth": "Most common patterns: No mutations (170 patients, avg age 59.94), ATRX-IDH1-TP53 (167 patients, avg age 38.41), IDH1 only (146 patients, avg age 46.38)",
    "derivation": "Complex clustering analysis of mutation patterns",
    "type": "Statistics",
    "subtype": "Classification and Clustering",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Analyze the trend of mutation frequencies (IDH1, TP53, ATRX) across different age groups.",
    "ground_truth": "Age <30: IDH1 (82.9%), TP53 (72.4%), ATRX (63.2%); Age 30-45: IDH1 (83.3%), TP53 (59.8%), ATRX (44.3%); Age 45-60: IDH1 (38.0%), TP53 (30.2%), ATRX (15.3%); Age 60+: IDH1 (14.9%), TP53 (26.3%), ATRX (8.0%)",
    "derivation": "Mutation frequencies calculated by age group using groupBy and frequency counts",
    "type": "Statistics",
    "subtype": "Trend Analysis and Smoothing",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Based on the mutation data, what might explain the relationship between IDH1 mutation status and patient age at diagnosis?",
    "ground_truth": "IDH1 mutated patients are significantly younger (mean 41.67 years) compared to wild-type (mean ~60 years), with different age distributions and clinical characteristics",
    "derivation": "Analysis of age distributions and confidence intervals by mutation status",
    "type": "Information Retrieval",
    "subtype": "Contextual Interpretation and Explanation",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "What is the relationship between age, gender, and mutation patterns?",
    "ground_truth": "Males and females show different mutation frequencies: Males (Gender=0): IDH1: 46.1%, TP53: 41.4%, ATRX: 23.8%; Females (Gender=1): IDH1: 51.0%, TP53: 41.6%, ATRX: 28.8%",
    "derivation": "Analyzed gender-specific mutation rates using data grouping and frequency calculations",
    "type": "Statistics",
    "subtype": "Correlation and Association",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Analyze the distribution of risk profiles based on mutation combinations.",
    "ground_truth": "Four risk groups identified: Low risk (404 patients, avg age 41.64), High risk (203 patients, avg age 60.89), Mixed (12 patients, avg age 41.39), No risk mutations (220 patients, avg age 59.35)",
    "derivation": "Created risk profiles based on combinations of high-risk (EGFR, PTEN) and low-risk (IDH1, CIC) mutations",
    "type": "Statistics",
    "subtype": "Classification and Clustering",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "What are the racial differences in mutation frequencies, if any?",
    "ground_truth": "Race 0 (n=765): IDH1 49.8%, TP53 42.7%, ATRX 26.3%; Race 1 (n=59): IDH1 25.4%, TP53 30.5%, ATRX 22.0%; Race 2 (n=14): IDH1 57.1%, TP53 21.4%, ATRX 21.4%",
    "derivation": "Calculated mutation rates by racial groups using groupBy and frequency analysis",
    "type": "Information Retrieval",
    "subtype": "Multi-Column Analysis and Summarization",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"

},
{
    "question": "Calculate the mutation burden distribution across the dataset.",
    "ground_truth": "Distribution of number of mutations per patient: 0: 124 patients, 1: 213 patients, 2: 262 patients, 3: 201 patients, 4: 35 patients, 5-7: 4 patients",
    "derivation": "Counted total number of mutations per patient and created frequency distribution",
    "type": "Statistics",
    "subtype": "Frequency and Distribution Analysis",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "What is the relationship between IDH1 mutation and glioma grade?",
    "ground_truth": "In Grade 0 gliomas, 381/487 (78.2%) are IDH1-mutant, while in Grade 1 gliomas, only 23/352 (6.5%) are IDH1-mutant",
    "derivation": "_.groupBy(data, 'Grade'); _.mapValues(groups, g => _.countBy(g, 'IDH1'))",
    "type": "Statistics",
    "subtype": "Correlation and Association",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "Is there an age difference between IDH1-mutant and IDH1-wildtype gliomas?",
    "ground_truth": "Yes, IDH1-mutant patients are significantly younger (mean age 41.7 years) compared to IDH1-wildtype patients (mean age 59.5 years)",
    "derivation": "_.groupBy(data, 'IDH1'); calculate mean age for each group",
    "type": "Statistics",
    "subtype": "Descriptive Statistics",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "What is the co-occurrence pattern of IDH1 and TP53 mutations?",
    "ground_truth": "Of IDH1-mutant cases, 238/404 (58.9%) have TP53 mutation. Of IDH1-wildtype cases, only 110/435 (25.3%) have TP53 mutation",
    "derivation": "_.countBy(data, row => `IDH1:${row.IDH1},TP53:${row.TP53}`)",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "What is the distribution of gender in the dataset and how does it relate to mutation status?",
    "ground_truth": "There are 488 females (58.2%) and 351 males (41.8%) in the dataset",
    "derivation": "_.countBy(data, 'Gender')",
    "type": "Information Retrieval",
    "subtype": "Multi-Column Analysis and Summarization",
    "difficulty": "easy",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "What proportion of lower-grade (Grade 0) gliomas have IDH1 mutations?",
    "ground_truth": "Of Grade 0 gliomas, 381/487 (78.2%) have IDH1 mutations",
    "derivation": "filterByGrade(data, 0).filter(row => row.IDH1 === 1).length / filterByGrade(data, 0).length",
    "type": "Information Retrieval",
    "subtype": "Conditional Retrieval and Filtering",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "Is there evidence of mutual exclusivity between EGFR and IDH1 mutations?",
    "ground_truth": "Yes, among 112 EGFR-mutant cases, only 4 (3.6%) have IDH1 mutations, suggesting strong mutual exclusivity",
    "derivation": "_.countBy(data, row => `EGFR:${row.EGFR},IDH1:${row.IDH1}`)",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "Do molecular profiles differ by patient age?",
    "ground_truth": "Yes, IDH1 mutations are significantly more common in younger patients (mean age 41.7 vs 59.5 years), suggesting distinct molecular pathways in different age groups",
    "derivation": "compare mean age between IDH1-mutant and wildtype groups",
    "type": "Statistics",
    "subtype": "Correlation and Association",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "What is the frequency of ATRX mutations in IDH1-mutant vs IDH1-wildtype gliomas?",
    "ground_truth": "Of the 217 ATRX-mutant cases in the dataset, 189 (87.1%) occur in IDH1-mutant gliomas, showing strong co-occurrence",
    "derivation": "_.countBy(data, row => `ATRX:${row.ATRX},IDH1:${row.IDH1}`)",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "What is the frequency of concurrent mutations in the PI3K pathway (PIK3CA, PIK3R1, PTEN)?",
    "ground_truth": "Only 3 cases (0.36%) show concurrent PIK3CA and PIK3R1 mutations, while 591 cases (70.4%) have no mutations in any of these genes",
    "derivation": "_.countBy(data, row => `PIK3CA:${row.PIK3CA},PIK3R1:${row.PIK3R1},PTEN:${row.PTEN}`)",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "Is there evidence of mutual exclusivity between PTEN and PIK3CA mutations?",
    "ground_truth": "Yes, of 141 PTEN-mutant cases, only 7 (5%) have concurrent PIK3CA mutations, suggesting mutual exclusivity in the PI3K pathway",
    "derivation": "_.countBy(data.filter(row => row.PTEN === 1), 'PIK3CA')",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "How does IDH1 mutation frequency vary across racial groups?",
    "ground_truth": "IDH1 mutation frequencies vary by race: Race 0 (49.8%), Race 1 (25.4%), Race 2 (57.1%), showing significant variation in molecular profiles",
    "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'IDH1'))",
    "type": "Information Retrieval",
    "subtype": "Multi-Column Analysis and Summarization",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "Is there a difference in EGFR mutation frequency across racial groups?",
    "ground_truth": "EGFR mutation rates vary: Race 0 (12.8%), Race 1 (22.0%), Race 2 (7.1%), suggesting potential racial differences in molecular pathways",
    "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'EGFR'))",
    "difficulty": "hard",
    "subtype": "Demographic Analysis",
    "type": "comparison",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "How does IDH1 mutation frequency vary across racial groups?",
    "ground_truth": "IDH1 mutation frequencies vary by race: Race 0 (49.8%), Race 1 (25.4%), Race 2 (57.1%), showing significant variation in molecular profiles",
    "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'IDH1'))",
    "type": "Information Retrieval",
    "subtype": "Multi-Column Analysis and Summarization",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "Is there a difference in EGFR mutation frequency across racial groups?",
    "ground_truth": "EGFR mutation rates vary: Race 0 (12.8%), Race 1 (22.0%), Race 2 (7.1%), suggesting potential racial differences in molecular pathways",
    "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'EGFR'))",
    "type": "Information Retrieval",
    "subtype": "Multi-Column Analysis and Summarization",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "What is the pattern of co-occurrence between EGFR and PDGFRA mutations?",
    "ground_truth": "Of 112 EGFR-mutant cases, only 5 (4.5%) have concurrent PDGFRA mutations, while 710 cases (84.6%) have neither mutation",
    "derivation": "_.countBy(data, row => `EGFR:${row.EGFR},PDGFRA:${row.PDGFRA}`)",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "medium",
    "table_path": "./datasets/research/Glioma.csv"
},
{
    "question": "Are PDGFRA mutations associated with specific molecular subtypes?",
    "ground_truth": "Of 22 PDGFRA-mutant cases, 17 (77.3%) occur in EGFR-wildtype tumors, and 16 (72.7%) in IDH1-wildtype tumors, suggesting a distinct molecular subtype",
    "derivation": "analysis of PDGFRA mutants with EGFR and IDH1 status",
    "type": "Statistics",
    "subtype": "Correlation and Association",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},


{
    "question": "Does the IDH1-ATRX-TP53 triple-positive signature represent a distinct biological entity, and what are its clinical implications?",
    "ground_truth": "171 cases (20.4%) show triple-positive signature, with mean age 38.5 years and strong enrichment in Grade 0 (90.1% of triple-positive cases), suggesting a distinct biological subtype with better prognosis",
    "derivation": "Analysis of co-occurrence patterns and clinical features in triple-positive cases",
    "type": "Statistics",
    "subtype": "Classification and Clustering",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "How do alterations in the RTK/PI3K pathway members (EGFR, PDGFRA, PIK3CA, PIK3R1, PTEN) cooperate to drive gliomagenesis, and do they define specific molecular subtypes?",
    "ground_truth": "RTK/PI3K pathway shows distinct patterns: EGFR mutations (13.3%) are mutually exclusive with PDGFRA (2.6%), while PIK3CA/PIK3R1 mutations show limited co-occurrence with PTEN loss, suggesting different mechanisms of pathway activation",
    "derivation": "Complex pathway analysis including mutual exclusivity and co-occurrence patterns",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "Do the distinct molecular profiles in different age groups suggest different cellular origins or evolutionary paths in glioma development?",
    "ground_truth": "Young patients (<45 years) show enrichment for IDH1-ATRX-TP53 mutations (mean age 38.5), while older patients show EGFR/PTEN alterations (mean age 60.7), suggesting distinct developmental pathways",
    "derivation": "Integration of age patterns with molecular subtypes",
    "type": "Statistics",
    "subtype": "Classification and Clustering",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "How does the interplay between chromatin modifiers (ATRX, SMARCA4, BCOR) and metabolic alterations (IDH1/2) influence glioma development and progression?",
    "ground_truth": "ATRX mutations strongly co-occur with IDH1 (87.1%) but rarely with SMARCA4/BCOR, suggesting distinct chromatin-regulatory mechanisms in IDH-mutant vs wildtype gliomas",
    "derivation": "Analysis of chromatin modifier co-occurrence patterns and associations",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "How can the distinct molecular subtypes in glioma inform personalized treatment strategies and clinical trial design?",
    "ground_truth": "Four major molecular subtypes identified: IDH-triple (20.4%, mean age 38.5), IDH-only (19.8%, mean age 45.8), RTK/PI3K (24.8%, mean age 60.3), and Other (35%, mean age 54.4). Each shows distinct grade distributions and mutation patterns, suggesting different therapeutic vulnerabilities",
    "derivation": "Integration of molecular subtypes with clinical characteristics",
    "type": "Statistics",
    "subtype": "Classification and Clustering",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "What do the age-specific molecular patterns reveal about glioma biology across different populations, and how should this inform screening and prevention strategies?",
    "ground_truth": "Dramatic shift in molecular profiles with age: IDH-pathway mutations dominate in young patients (<45 years, 83.3%), while RTK/PI3K alterations predominate in older patients (>60 years, 47.2%). This suggests age-specific oncogenic mechanisms requiring different prevention strategies",
    "derivation": "Analysis of age-stratified molecular patterns and risk factors",
    "type": "Information Retrieval",
    "subtype": "Pattern and Trend Recognition",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "How do the distinct molecular subtypes suggest different evolutionary trajectories in glioma, and what are the implications for treatment resistance?",
    "ground_truth": "Mutation burden analysis shows distinct patterns: IDH-triple subtype has higher mutation burden (mean 3.2 mutations) vs RTK/PI3K subtype (mean 1.8 mutations), suggesting different genomic stability mechanisms and potential resistance pathways",
    "derivation": "Integration of mutation burden, pathway analysis, and clinical correlations",
    "type": "Statistics",
    "subtype": "Classification and Clustering",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
},

{
    "question": "How should molecular subtype distributions influence clinical trial design and interpretation in glioma?",
    "ground_truth": "Four distinct molecular subtypes with different ages of onset and clinical features suggest need for subtype-specific trial design: IDH-triple (young, good prognosis), RTK/PI3K (older, poor prognosis), requiring different endpoints and stratification strategies",
    "derivation": "Analysis of subtype-specific characteristics and outcomes",
    "type": "Information Retrieval",
    "subtype": "Summary and Reporting from Tables",
    "difficulty": "hard",
    "table_path": "./datasets/research/Glioma.csv"
}

]
